Eosinophilic oesophagitis: recent advances and practical management

Stephen Attwood, Jenny Epstein

ABSTRACT

Eosinophilic oesophagitis (EoE) is a disease identified just over 30 years ago. The main symptom is dysphagia. EoE is initially inflammatory and progresses to fibrosis. There are differences in clinical presentation between young children and adults. Diagnosis is by endoscopy and six biopsies at varying positions of the oesophageal lining. Blood tests are of no diagnostic value as the condition is mediated by IgG4 local mucosal pathology. Endoscopic signs are distinct from those of gastro-oesophageal reflux. Histological signs of EoE are >15 eosinophils/high-power field on a background of hyperplastic mucosa. Options of therapy include diet restriction, proton pump inhibitors therapy and topical steroids but there is a dearth of randomised control trials to define the optimum approach. The only licenced therapy for EoE is budesonide orodispensible tablet, a specific formulation for oesophageal topical steroid therapy. EoE is the most common cause of spontaneous perforation in the oesophagus. Stricture formation occurs in up to 10% and may require therapeutic dilatation.

INTRODUCTION

The diagnosis that every gastroenterologist needs to know about for the 2000s is eosinophilic oesophagitis (EoE). Since its initial description in 1993 and its eventual accreditation with International Classification of Diseases-10 code (K.20.0) in 2011, EoE has become the second most common oesophageal disease and arguably the most common cause of dysphagia in young people.

Eosinophilic inflammation may arise anywhere in the gastrointestinal tract, although the most common and best categorised disease site is that seen in EoE. In health, eosinophils have a sentinel function and are present in small numbers throughout the gut except the oesophagus. They protect against helminthic and other infections. In disease, symptoms are diverse and depend on the site of inflammation, both in terms of position from oesophagus to colon, and position within the layers of the wall (mucosal causing diarrhoea; serosal causing ascites).

The symptoms in EoE are caused by difficulties during passage of food through the oesophagus. Patients feel food stick after swallowing, or a chest discomfort—central, upper, mid or lower. They may use the terms ‘indigestion’ or ‘heartburn’ but not realise they differ in nature from discomfort felt by people who suffer acid reflux. The symptoms occur during or immediately after swallowing, during a meal. This contrasts with reflux which occurs postprandially. The patient may describe regurgitation, if swallowed fluids (saliva or drinks) cannot pass the stuck food bolus. This does not taste acidic, nor of gastric content and is quite distinct from the regurgitation in gastro-oesophageal reflux disease (GORD).

The condition is inflammatory, with a predominant eosinophilic inflammation, and progressively fibrotic. Both the primary inflammation and fibrosis contribute to the relative obstruction to passage of solid foods, resulting in dysphagia, food bolus obstruction, odynophagia and awareness of slow food passage. EoE sufferers find they are last to finish a meal, use large amounts of liquid to wash food down, or suffer the indignity of all subsequent swallowed saliva, fluids or solids until the bolus has shifted. When this occurs while eating in public this creates added stress.

EoE is a disease of younger people—children and young adults. The manifestation of EoE symptoms in children may differ from that in adults. Parental interpretation of their child’s eating difficulty may be relayed as regurgitation or food refusal, both possibly due to dysphagia and temporary bolus obstructions. A young child approaching solid food for
the first time may not know the circumstance of normal swallowing or eating food of normal solid consistency. Dysphagia and behavioural difficulties associated with eating in young children may be expressed differently to those who acquire the symptom in adulthood. EoE in children may also arise on a background of other food intolerances and allergies. Infants and toddlers tend to present with non-specific symptoms such as feeding difficulties, failure to thrive, regurgitation and discomfort; while in mid-school-age children abdominal pain and vomiting become more prominent. In older children the presentation of EoE changes due to progression of fibrosis, with the adult phenotype of dysphagia and food impaction.

Children and their carers adapt to their symptoms, with unconscious behavioural modifications to food choices and eating patterns. Clinicians need to maintain suspicion of EoE; taking focused history with specific questions about eating adaptations, excessive water drinking, solid texture avoidance and slow eating.

Epidemiology
When first described EoE was regarded as rare. In the past decade there has been rapid rise in prevalence throughout the western world, with mean estimates at 15/100 000 before 2007 and 63/100 000 since 2017. This puts the condition on par with inflammatory bowel disease. The peak incidence is seen in young adults (third and fourth decade) but recognised in all ages. It is three times commoner in males and associated with other atopic diseases such as allergic asthma, rhinitis and eczema.

The complication of food bolus obstruction is the most frequent emergency presentation of EoE, occurring in 20% of sufferers. EoE is the most common cause of acute food bolus obstruction seen in emergency departments, the most common cause of spontaneous oesophageal perforation with presentation and character significantly different from that seen in Boerhaave syndrome (see Complications: Perforation). There is seasonality in presentation of EoE, more new diagnoses being made in spring and summer. Food bolus impactions occur more frequently in summer and autumn. This implies an environmental trigger, possibly airborne but it could equally relate to seasonal availability of foods.

Diagnosis
The only avenue to a diagnosis of EoE is to assess the histology of the oesophageal mucosa. That requires an endoscopy, which itself may reveal characteristic signs of EoE such as linear furrows, rings or trachealisation, microabscesses, mucosal fragility, oedema, stricture or narrow bore oesophagus. In 10%–20% of adults, and more in children, the oesophagus may appear normal. Regardless of the presence or absence of indicative signs of EoE every patient with dysphagia, or atypical childhood presentation of significant oesophageal symptoms requires biopsy. As inflammation is patchy biopsies must be multiple and multi-focal. Studies have identified that six samples are needed, either two each from lower, mid and upper oesophagus, or three from each half, whichever is most convenient.

The presence of dense infiltration of eosinophils within the oesophageal epithelium with a peak concentration of >15 eosinophils/high-power field (hpf) is the distinguishing feature of EoE from other diseases. Although GORD may have a few eosinophils present these are usually less than 5/hpf. Both GORD and EoE show histological features of hyperplastic mucosa with increased basal zone thickness and increased papillary height. In both some degree of increased cellular spacing may occur. In GORD the inflammation is usually restricted to the lower oesophagus and worst at the GE junction, whereas in EoE the inflammation may be patchy, scattered throughout the oesophagus. A common error is to assume that biopsies near the oesophago-gastric junction showing high density of eosinophils relate to GORD but this more likely to represent EoE because high density eosinophilia is rare in GORD.

It is important to understand that in adulthood EoE and GORD are separate conditions. They present with different gender and atopy background. Symptoms differ in character and come on at different times—during meals for EoE but after meals or at night for GORD. They look completely different endoscopically and they have a different range of histological appearances. They have different causes with acid reflux inducing GORD but antigen driven immune reactivity in EoE. As GORD is common, being seen in up to 30% of our adult population it is possible for both to coexist.

Some diseases such as achalasia, Chagas disease and hypereosinophilic syndromes, may possibly have an oesophageal eosinophil infiltrate but these are much less frequent, and most of these patients do not have >15 eosinophils/hpf.

There are no blood tests for diagnosis of EoE. The underlying pathology in EoE is an IgG, mucosal reaction in which there is little systemic involvement. In a small proportion of patients, peripheral eosinophil counts may be elevated but this is non-specific, and insensitive. Tests of IgG, IgE or IgA levels are not helpful. If allergy tests are used they contribute to the management of coexistent asthma or eczema but do not contribute to diagnosis or management of EoE. Tests of skin reactivity are not correlated with oesophageal reactivity in adults, and poorly correlated in children. Although it is possible to use the Oesophageal String test, this is currently not available as a diagnostic indicator. Work is underway to assess its value in monitoring response to therapy.

In young children overlap between GORD and EoE is relatively common; GORD in infants and toddlers
being driven by underlying milk allergy, yielding borderline mucosal eosinophil counts and often responding to the exclusion of milk from the diet. This is a frequent source of diagnostic uncertainty, not least because treatments common to both infantile GORD and EoE, namely milk-free diet and proton pump inhibitors (PPI) medication are used empirically before endoscopy.

The main issue for most patients with EoE is a reduction in quality of life, with social restrictions, difficulties with eating and dietary problems. These are the factors that drive the majority of patients to seek medical help.

Therapy
No published guideline gives directions about the best therapeutic option in EoE due to a distinct lack of comparative randomised controlled trials. No one, simple, algorithm is likely to fit all patients. The following arguments represent the experience of the authors and will understandably differ from others.

Decisions on treatment of EoE require assessment of the impact the disease has on the patient’s life and an understanding of the patient’s own philosophy regarding treatment options. During the initial assessment, symptom severity should be recorded. Symptom frequency varies from every meal and every day to only once or twice a week, or month. Symptom severity ranges from food bolus obstruction requiring emergency attendance to minor and intermittent dysphagia. Many patients adapt well by modifying their diet, mincing their food, liquidising their vegetables and surviving on soups, smoothies and liquids.

Clinicians should describe the treatment options alongside their impact on the patient’s quality of life and likelihood of future normal eating.

Diet
If food antigens are responsible for oesophageal eosinophilic inflammation, then their exclusion should be a simple therapy. Unfortunately, most patients react to multiple food types. Currently there are no reliable methods of ascertaining which foods are responsible. Skin prick testing identifies allergens associated with IgE-mediated atopy such as eczema and rhinitis but not the IgG4 EoE. Two practical approaches to diet are in use—a step up 2–4–6 food elimination and a step down 6-food elimination. Both require careful support by dietitians experienced in EoE. Both require follow-up and investigation to identify if initial symptom improvements are likely to provide a long-lasting therapeutic strategy. There is poor correlation of symptoms and histological improvement in EoE, partly related to placebo type responses, and partly to the influence of dietary behaviours and food avoidance by the patients.14–16

The foods that stick during swallowing are usually not the foods that are the source of pro-inflammatory drive. Over the past decade the most common approach has been the elimination of multiple foods—milk, wheat, eggs, soya, nuts and fish. Often called the 6-food elimination diet this is a misnomer as the number of food types excluded in studies is often more, often excluding legumes. The range of success is 50%–75% of patients after 12 weeks, requiring both symptom check and endoscopy with biopsy to ascertain true remission.14 15 17 It is difficult to maintain a diet excluding all these food types, less than 10% of patients sustaining 6-food elimination for 12 months.14 15

A simpler approach, the 2–4–6 step up diet is growing in popularity. Excluding milk and wheat is successful in 40% of patients and this is cheap, using a single follow-up endoscopy and practical to sustain.18

The decision regarding those who fail the 2-food elimination is more complex, as stepping up to four and then six foods introduces the difficulties of multiple endoscopies and difficulties in sustaining the diet. The decision on whether a patient persists with a dietary approach or switches to a drug therapy is an individual one that requires counselling.

Dietary therapies are equally efficacious in children and adults but used more in paediatric than adult settings. This may be driven by clinicians’ and carers’ reluctance to use steroids in children and, especially in younger children, the ability to impose restricted diets. The same foods are implicated in paediatric and adult EoE. There is evidence that allergy testing plays a slightly more useful role in children than adults in guiding the selection of diet. This may reflect the gradual switch over time of EoE from IgE-mediated to IgG4-mediated disease, hence the increased prevalence of IgE-based testing in childhood. Milk remains the most common food trigger and exclusion of milk should always be part of the initial dietary approach.

Drug therapy: PPI
Despite the lack of acid reflux in the aetiology of EoE there is a symptom response in 30%–60%19 of patients in observational and uncontrolled studies, when double dose PPI (20 mg omeprazole two times per day or equivalent) are used for 6 weeks. Prospective studies of their use in routine practice are less optimistic.20 Outcomes of PPI in children are also less than those seen in adults.21 Due to their low cost and availability most recommend starting therapy with a PPI, checked with endoscopy and a standard severity questionnaire to ensure objectivity to the assessment. If GORD coexists with EoE—which may occur in 10%–20% of patients—then PPI may have benefit for the reflux symptoms of heartburn.

Drug therapy: topical steroid
The most effective specific therapy for EoE is topical steroid.22 23 Until the introduction of special oesophageal formulations their use was restricted by the
complexity of administering formulations intended for bronchial asthma. This caused confusion in administration, dosage and clear patient information. Fluticasone spray (250 μg four puffs two times per day, last thing at night and after breakfast with no mouth washing, food or fluids for as long as possible) is suitable for adults, or a viscous solution of oral budesonide, variably formulated in hospital pharmacies and the previous standard of therapy in children, are effective but both lack consistency in delivery and formulations. This has driven the need for a dedicated formulation now available as an orodispensible budesonide tablet, which can be placed on the tongue and allowed to dissolve in saliva passing gradually into the oesophagus. In placebo-controlled trials, this is highly effective in symptom resolution and histological remission (85% at 12 weeks). Symptom remission improves with longer duration of therapy and is a feature of the time it takes for fibrosis in EoE pathophysiology to normalise. Fibrosis takes a long time to develop and in some a long time to resolve. There may be patients who require a therapeutic dilatation. They must have continuation of topical steroid as their maintenance therapy. Safety of long-term budesonide for GI complaints is well established and the occasional oral thrush easily managed by oral nystatin suspension for 10 days, without cessation of therapeutic topical steroids.

General considerations in choosing first line therapy
In patients with severe (daily) symptoms, history of food bolus obstruction or those who have already had a trial of PPI, topical steroids may be the first line therapy. There is no value in using systemic steroids as they do not produce a greater concentration of steroid at the site of action (the oesophageal epithelium) and they have severe untoward side effects when used for long periods. Topical steroids need to be used for 3 months in the first instance and thereafter in maintenance therapy or in repeated bolus courses of 3 months. Work is on-going to define which of these approaches is appropriate.

With moderate symptoms, mild symptoms or occasional self-resolving bolus obstruction first use diet or PPI. In practice many patients have already tried PPI. The balance of using a cheap but unlicensed drug in the setting of needing more endoscopic checks must be offset against the costs of a licenced effective therapy. Dietary therapy is suited to well-motivated patients in whom there is a likelihood that they will comply with their diet in the long term. The lower the number of foods to avoid the easier that is to achieve. In children concerns around growth and weight gain can complicate instigation of restricted diets although EoE is not associated with reduced final height attainment. Long term dietary restrictions are challenging to adhere to especially in adolescence. Decision making between dietary and drug treatment is therefore typically led by individual and family preferences rather than medical factors, since efficacy of the two approaches are comparable.

Follow-up
Guidelines required endoscopy and follow-up to assess both symptoms and histology with all types of therapy. The problem of needing to objectify disease response is because symptomatic responses are poor and have poor correlation with histological response, as is the case with PPI and dietary regimes. It might be that future guidelines could omit an endoscopy if >90% have histological remission and 85% symptom improvement after 12 weeks with orodispensible budesonide, thereby reducing overall costs.

In paediatric practice there is an inherent challenge in the long-term management of EoE as the disease returns when the treatment is stopped. The safety of long-term swallowed steroid is not entirely established although evidence suggests it has a good safety profile in up to 2 years of continuous use in children. Monitoring for adrenal suppression is recommended.

Early fibrosis in EoE may be reversible, more so in childhood. If it becomes established it can lead to irreversible complications such as stricture, food bolus impaction and perforation, more commonly seen in adults.

Complications
Food bolus obstruction
EoE is now the most common cause of food bolus obstruction presenting to emergency departments. Although often treated by Ear Nose and Throat surgeons, there are good reasons for food bolus obstruction to be managed by gastroenterologists, as long as the airway is not compromised.

Management: Many patients tolerate temporary food bolus obstruction over a number of hours, and there is no clear definition of when emergency treatment is necessary. Most patients present to an Emergency Department within 4 hours, and much sooner if symptoms are distressing. The initial management is conservative, with reassurance, intravenous fluids and a clinical assessment to rule out perforation, excluding cervical surgical emphysema or ‘crepitus’. If pain is predominant perform a chest X-ray to detect free air. Antispasmodics or muscle relaxants have no value. An urgent endoscopy should be arranged, with protection of the airway during bolus extraction. This may involve a general anaesthetic. At the first endoscopy make a full assessment of the cause, before or after careful extraction of the bolus. Biopsy above, below and at the site of obstruction should be performed. It is unfortunate that the lack of knowledge that EoE is the most common cause of bolus obstruction leads to lengthy delays of therapy and recurrence in many patients. The authors strongly advise biopsy at the index endoscopy to avoid diagnostic failures.
**Conclusion**

With a structured approach to therapy, supported by standardised patient questionnaires to make a reproducible assessment of symptom severity and supported by endoscopic assessment of remission, therapy in EoE is usually successful. More than 90% of patients can be treated effectively in the authors’ experience and failures are more often related to issues of compliance with the planned therapy than to failure of all three therapies completely. Although some biological agents are being developed that may directly interfere with the pathogenesis of eosinophil biology their expense and their potential side effects may give them only a limited role in EoE. In patients with multiple gastrointestinal eosinophilic diseases, a rare circumstance, such new drugs may have special value.

**Psychosocial complications of therapy**

Patients left on elimination diets find them difficult to follow for social and practical reasons. Their quality of life becomes impeded despite improvement in EoE symptoms. Particularly in children and adolescents, the effects of the treatment by diet may be worse than the disease. Discuss the burden of therapy as well as the burden of disease when counselling patients and their families about the management of EoE.

**Contributors**

Both authors contributed directly to the development, writing and editing of this review.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

SA is a paid speaker for the following companies related to the treatment of oesophageal diseases, Dr Falk Pharma, Medtronic Inc and research advisor to Dr Falk Pharma. AstraZeneca and EsoCap. JE is a paid speaker and advisor to Dr Falk Pharma. Both authors are voluntary advisors to EosNetwork, Euros and the BSG Guideline Development group, and JE an advisor to ESPGHAN guidelines.

**Patient consent for publication**

Not required.

**Provenance and peer review**

Commissioned; externally peer reviewed.

**ORCID iD**

Stephen Attwood http://orcid.org/0000-0002-5761-157X

**References**


